Austin Bigley

Company: Indapta Therapeutics

Job title: VP, Head of Research and Development

Seminars:

Roundtable : Re-Assessing the Role of Lymphodepletion in the Allogeneic Setting 3:00 pm

Using enhanced pre-conditioning regimens to increase cell persistence to potentially maximize clinical benefit from the therapy Reducing the risk of immunogenicity of allogeneic immune effector cells with alternative immunomodulatorsRead more

day: Advancing Durability & Persistence Focus Day

Creating Novel Dosing Regimens for Greater Patient Success 2:00 pm

Delving into a new strategy for a superior dosing protocol that will set patients up for long-lasting treatment and minimise patient relapse Exploring the potential to re-construct dosing regimens with allogeneic cell therapies through repeated dosing protocolsRead more

day: Advancing Durability & Persistence Focus Day